New advances in HCC diagnosis, staging and treatment all predicted to improve …Medical XpressIn Japanese patients, 59% were within the Milan Criteria (generally accepted set of parameters designed to assess the suitability of HCC patients for liver t…
ISHLT to Announce Results of NOVEL Lung Trial Show Great Promise for …PR Web (press release)The International Society for Heart and Lung Transplantation (ISHLT) will announce today the one-year outcomes of the NOVEL lung trial, the first prospective …
|
ISHLT Releases Latest Interim Results of INSPIRE Lung Transplantation Trial …
PR Web (press release) Today the latest results and research progress of the prospective INSPIRE trial, initiated in late 2011, will be announced at the International Society for Heart and Lung Transplantation’s 34th Annual Meeting and Scientific Sessions. The presentation … |
|
ISHLT Releases Latest Interim Results of INSPIRE Lung Transplantation Trial …
DigitalJournal.com Today the latest results and research progress of the prospective INSPIRE trial, initiated in late 2011, will be announced at the International Society for Heart and Lung Transplantation’s 34th Annual Meeting and Scientific Sessions. The presentation … ISHLT to Announce Results of NOVEL Lung Trial Show Great Promise for …PR Web (press release) |
Hepatitis C treatment cures over 90 percent of patients with cirrhosisEurekAlert (press release)The physicians are professors and teach at University Hospital of the University Health System and are involved with the liver transplantation program of th…
The Pharma Letter |
New data reveals positive outcomes for hepatitis C transplant patients
Eureka! Science News Hepatitis C infection is a common cause of liver transplantation, with virus-related diseases comprising 40% of primary indications for liver transplantation in Europe among patients with cirrhosis. More than 5,500 liver transplantations are currently … Sovaldi Continues to Excel in Trials with Hep C, Advanced Liver DiseaseDrug Discovery & Development Encouraging Results on Gileads SovaldiZacks.com |
Economic Times |
Encouraging Results on Gileads Sovaldi
Zacks.com In the second study – a single-arm open-label phase II study (GS-US-334-0126: n=40) – patients suffering from established recurrent HCV infection after liver transplantation received up to 24 weeks of therapy with Sovaldi and ribavirin. Results … Gilead’s Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C …Stockhouse Gilead’s Sovaldi Shows Efficacy & Safety In Chronic Hepatitis C PatientsNASDAQ Gilead’s Sovaldi® Demonstrates Efficacy and Safety Among Chronic …Businessweek |
|
EASL updates recommendations for HCV management
Healio Another key message in terms of special populations was that patients with cirrhosis or those who have or will undergo liver transplantation should receive treatments that are interferon-free. “My last point is that we have no data for hemodialysis … |
|
NASH with liver transplantation related to early CVD mortality
Healio LONDON — Patients who underwent perioperative liver transplantation and had nonalcoholic steatohepatitis were at increased risk for early cardiovascular disease-related mortality, according to research presented today at the International Liver Congress. |
Drug Discovery & Development |
Sovaldi Continues to Excel in Trials with Hep C, Advanced Liver Disease
Drug Discovery & Development Study GS-US-334-0126 was a single-arm open-label Phase 2 trial in which patients with established recurrent HCV infection following liver transplantation received up to 24 weeks of therapy with Sovaldi plus RBV (escalating doses starting at 400 mg/day). New data reveals positive outcomes for hepatitis C transplant patientsEureka! Science News |